Cellular and Molecular Evidence of Multiple Sclerosis Diagnosis and Treatment Challenges

Journal of Clinical Medicine, Год журнала: 2023, Номер 12(13), С. 4274 - 4274

Опубликована: Июнь 26, 2023

Multiple sclerosis (MS) is a chronic autoimmune disease that impacts the central nervous system and can result in disability. Although prevalence of MS has increased India, diagnosis treatment continue to be difficult due several factors. The present study examines difficulties detecting treating multiple India. A lack knowledge among healthcare professionals general public, which delays treatment, one significant issues. Inadequate numbers neurologists with management also exacerbate situation. In addition, medications are expensive not covered by insurance, making them inaccessible most patients. Due absence established protocols standards for care, India’s techniques vary. population diversity poses unique challenges regarding genetic variations, cellular molecular abnormalities, potential differing responses. more accurately diagnose monitor specialized medical supplies diagnostic instruments. Improved awareness education as well development standardized regimens investment research infrastructure, required address these By addressing issues, it anticipated India will improve, leading better outcomes those affected this condition.

Язык: Английский

---

Fluorine in the pharmaceutical industry: Synthetic approaches and application of clinically approved fluorine-enriched anti-infectious medications

European Journal of Medicinal Chemistry, Год журнала: 2024, Номер 271, С. 116446 - 116446

Опубликована: Апрель 26, 2024

Язык: Английский

---

Lymphopenia associated with sphingosine 1-phosphate receptor modulators (S1PRMs) in multiple sclerosis: analysis of European pharmacovigilance data

Pharmacological Reports, Год журнала: 2025, Номер unknown

Опубликована: Апрель 9, 2025

Abstract Background The treatment landscape for Multiple Sclerosis (MS) has increased significantly over the past few decades, thanks to introduction of disease-modifying therapies (DMTs). Fingolimod, siponimod, ozanimod, and ponesimod belong newer generation oral DMTs categorized as sphingosine 1-phosphate receptor modulators (S1PRMs). Because their mechanism action, they may increase risk lymphopenia, which could influence therapeutic management people with MS. aim this study was describe compare reporting frequency lymphopenia related four S1PRMs. Methods Individual case safety reports (ICSRs) were retrieved from European spontaneous system database (EudraVigilance) January 1st, 2022, December 31st, 2023. odds ratios (RORs) computed probability between a S1PRM versus each other. Results We 4017 ICSRs, 521 (13%) reported associated fingolimod (53.3%), siponimod (38.4%), ozanimod (5.4%), (2.1%). most common source healthcare professional (94.2%), more than half ICSRs (62.6%) serious lymphopenia. Fingolimod lower compared siponimod. Both higher ozanimod; also had in comparison ponesimod. Conclusions relevant clinical implication disproportionality analysis is awareness these drugs, thus supporting proactive monitoring optimizing strategies Clinical trial number Not applicable.

Язык: Английский

---

1-Phosphate receptor agonists: A promising therapeutic avenue for ischemia-reperfusion injury management

International Immunopharmacology, Год журнала: 2024, Номер 131, С. 111835 - 111835

Опубликована: Март 19, 2024

Язык: Английский

---

Sphingosine-1-Phosphate Receptor Modulator – Siponimod: An Evaluation to Ameliorate Aluminium Chloride Induced Behavioural Change and Biochemical effects

Research Journal of Pharmacy and Technology, Год журнала: 2024, Номер unknown, С. 179 - 187

Опубликована: Янв. 19, 2024

Introduction: Alzheimer's disease (AD) is a neurodegenerative condition characterised by the gradual loss of hippocampal and cortical neurons, resulting in diminished memory cognitive function. Siponimod (SPM) selective modulator sphingosine 1-phosphate receptor subtype 1 5(S1P1,S1P5 receptors), was found to have neuroprotective effect neurological disorders. The present study conducted evaluate its beneficial effects AD. Materials Methods: In-silico molecular docking dynamic simulation studies were carried know potential interactions with selected target proteins. In-vivo inthirty rats divided randomly into five groups six per group: Control group received Carboxy methyl cellulose; administered aluminium chloride (AlCl3);standard rivastigmine (RVST) AlCl3; test SPM (0.05mg/kg 0.2mg/kg) AlCl3. Morris water maze elevated plus used learning memory. Behavioural changes biochemical parameters estimation performed at end experiment. Results: using protein ligands showed higher score stable acetylcholinesterase (AChE) SPM.Behavioural showed: decrease transfer latency time maze; reach platform increase spent quadrant treated rats. Biochemical evaluation marked malondialdehyde (MDA), nitrite, myeloperoxidase (MPO)levels increased antioxidant levels groups. exhibited significant inhibitory activity onAChE. Conclusion: be effective ameliorating AlCl3 induced observed benefits restoring attributed on AChE ability suppress free radical mediated oxidative damage.

Язык: Английский

---

Onboarding of siponimod in secondary progressive multiple sclerosis patients in Australia: Novel, real-world evidence from the MSGo digital support programme

Multiple Sclerosis Journal - Experimental Translational and Clinical, Год журнала: 2024, Номер 10(1)

Опубликована: Янв. 1, 2024

Background Siponimod is approved for use in people with secondary progressive multiple sclerosis (pwSPMS). An integrated digital platform, MSGo, was developed pwSPMS and clinicians to help navigate the steps of pre-siponimod work-up. Objective To explore real-world onboarding experiences siponimod amongst Australia. Methods Retrospective, non-interventional, longitudinal, analysis data extracted from MSGo (20 April 2022). The primary endpoint average time onboarding; endpoints were adherence sub-group analyses variables influencing onboarding. Results Mixed-cure modelling estimated that 58% participants ( N = 368, females 71%, median age 59 years) registered would ever initiate siponimod. initiation 56 days (95% CI [47–59] days). Half cited ‘waiting vaccination’ as reason delay. Cox regression found a nominated care partner had faster (HR 2.1, 95% [1.5–3.0]) more likely continue self-reporting daily dosing than those without 2.2, [1.3–3.7]). Conclusions Despite limitations self-reported challenges COVID-19 pandemic, this study provides insights into Australia demonstrates positive impact support.

Язык: Английский

---

Assessment of Stx-1A gene polymorphism (rs1569061) in relation to the development of multiple sclerosis in Egyptian patients

Egyptian journal of Immunology, Год журнала: 2024, Номер 31(02), С. 18 - 27

Опубликована: Апрель 1, 2024

Multiple sclerosis (MS) is a multifactorial polygenic disease; results from autoimmune and neurodegenerative processes which lead to multifocal lesions of the central nervous system. Axonal degeneration was found be prominent in inflammation period MS contribute progression disability. Soluble N-ethylmaleimide sensitive factor attachment receptor (SNARE) complex plays vital role release neurotransmitter by synaptic vesicle fusion. Stx-1A protein (Stx-1A), major component SNARE complex, widely expressed brain tissue. This study intended evaluate prevalence gene polymorphism (rs1569061) Egyptian population with investigate its association various clinical factors. included 65 adult patients 35 age- sex-matched normal control subjects. Diagnosis made an experienced neurologist according revised McDonald criteria. All Patients underwent full history taking, Age onset MS, disease duration, course degree disability Expanded Disability Status Scale (EDSS) family neurological diseases. genotyping performed TaqMan assay based quantitative real time (qPCR) verified sanger sequencer. Genotype allele frequencies did not differ significantly between case groups. No difference detected when comparing genotype frequency different parameters. Discrepancy minor (MAF) populations noted. In conclusion, our showed that no patient as regards frequency. Predicting studied population. However, discrepancy noted MAF for (rs1569061).

Язык: Английский

---

Progressive multiple sclerosis treatment considerations in the UK: Experience from trials and real-world population

Advances in Clinical Neuroscience & Rehabilitation, Год журнала: 2024, Номер unknown

Опубликована: Янв. 1, 2024

Язык: Английский

---